Table 2 B-cells subclusters in TIME-based on single-cell studies
From: Unravelling immune microenvironment features underlying tumor progression in the single-cell era
Tumor type | Sample | B-cell subsets | Key findings | Ref |
|---|---|---|---|---|
Breast cancer | Tumor | ICOSL+ B-cell (CR2, CD20, CD38/27, and IgA-IgD-) | B-cells elicit anti-tumor T-cell immunity by ICOSL | [159] |
Colorectal cancer | Adjacent tissue precancerous tissue and tumor | B-cell (CD40/27, KLRB1, and CCL5), plasma cell(MZB1, DUSP1, and CCL3) | CD40+/27+ B-cells decrease antigen presentation and antitumor immunity | [73] |
Melanoma | Tumor and peripheral blood | B-cells (MZB1, JCHAIN, and IGLL5) | B-cells can promote tumor immunotherapy response | [75] |
Non-small cell lung cancer | Tumor | Naïve-like B-cells, plasma-like B-cells | Two specific populations of B-cells regulate the growth of lung tumor cells | [78] |
Hepatocellular carcinoma | Tumor and adjacent tissue and lymph nodes | B-cells (MS4A1 and CD79A), plasma cells (IGLL1 and MZB1) | The infiltration levels of B-cells and plasma cells are low in liver cancer | [74] |